Table 3. Comparison of total progression-free survival and overall survival of triple sequences according to prognostic models of the MSKCC and Heng criteria.
| MSKCC/ Heng criteria | Favorable (mos., 95% CI) | Intermediate (mos., 95%C.I.) | Poor (mos., 95%C.I.) |
|---|---|---|---|
| PFS (p-value) | 0.183/ 0.248 | 0.041/ 0.012 | 0.317/ 0.273 |
| TT-TT-ITx | 33.9 (1-74.5) / 8.5 (1-56.5) | 14.1 (1-43.1) / 33.9 (1-74.5) | NA |
| ITx-TT-TT | 22.1 (17.9-26.3) / 22.1 (9.3-61.5) | 15.9 (4.4-27.4) / 16.7 (13.2-20.2) | 5* |
| TKI-mTORi-TKI | 17.8* | 23.3 (1-63.2) | 7.9* |
| TKI-TKI-mTORi | NA | 8.0 (1.0-15.0) | 14.1* |
| OS (p-value) | 0.030/0.090 | 0.078/ 0.006 | NA/ 0.317 |
| TT-TT-ITx | 67 (35.0-99.0) / 47.0 (9.6-162.4) | 40.0 (1-79.2) / 49 (19.7-63.3) | NA |
| ITx-TT-TT | 76 (1-154.4) / 111.0 (38.6-175.4) | 29 (1-71.1) / 53 (6.9-99.1) | NA/ 10* |
| TKI-mTORi-TKI | 25* | 33 (18.6-47.4) | NA |
| TKI-TKI-mTORi | 88* | 12.0 (7.2-16.8) | NA/ 21* |
*, only one patient’s outcome
C.I, confidence interval; PFS, progression-free survival; OS, overall survival